Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 483.00 476.00 490.00 483.00 482.00 482.00 17,720 08:00:31
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 31.7 6.6 11.4 42.4 224

Tristel Share Discussion Threads

Showing 3526 to 3546 of 3550 messages
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
DateSubjectAuthorDiscuss
25/11/2020
16:32
Perhaps more towards luck than deliberate timing! Have done this a lot with TSTL and always feel quite sad when I sell them and a bit nervous when I rebuy. I suspect a chance will come in the next few months sub 450.
zimbtrader
25/11/2020
13:30
Seems like a good call your sell. Well done. I holding patiently for now.
paraguay
25/11/2020
11:33
Sold off my entire holding last Friday at 524.8 and will still get the Divided. This needs positive US news and sustained global growth to push it to the next level.Hope to get back in sub 450 if it continues to slip down over the coming few months.
zimbtrader
12/11/2020
21:58
Ticking up nice and steady. Staying under the radar of the silly brigade. Just how I like it. Nobby no mates here on my tod.
paraguay
07/11/2020
08:28
Huge areas for growth.With India now on board and China the potential is huge. Then don't forget US and Canada after that once approval gained.This will be a growth company for a few years yet.
paulisi
05/11/2020
16:00
Maybe a number of investors also read the company's Q&A recently published and saw the clear potential for continued growth in a number of markets. In the UK, I can envisage that there may be a repeat drop in medical instrument disinfectant orders from the NHS, as non-urgent procedures are once again suspended, but surface disinfectant demand will hopefully more than compensate, as before. I hope that TSTL continues to underpromise and overdeliver. I think that huge potential remains.
james188
05/11/2020
15:33
530p on the ask now which must be an ATH. Momentum building nicely. I think it may be partly spurred by the fact that NHS appointments will surely not be postponed or cancelled as much as in LD1. Heady but worth it for a company that is in the best arena in these uncertain times.
mach100
02/11/2020
14:32
It is good that the results and Q&A are now available to look at closely. The MelloMonday BASH will feature Tristel this month on the 9th November and I think shareholders and potential investors will appreciate the analysis. The Mello Monday event starts at 6pm The full programme is available on the website. In the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four/five companies are a Buy Avoid Sell or Hold at this current juncture in the markets. Https://melloevents.com All investors welcome and if you use the code MMV5 you will get a half price ticket. Great investor content and entertainment. We had nearly 400 investors attend last month so these are very popular.
davidosh
02/11/2020
14:25
Tristel Final Results – Shareholder Q&A Question 4 What is the next major market that will start generating additional revenues and when? The next major market that will start generating revenue from scratch will be India, during the current financial year. hTTps://tristelresults.com/wp-content/uploads/2020/10/Tristel-Final-results-QA-FINAL.pdf - great news ... IMO.
piedro
29/10/2020
10:13
Tristel Global@TristelGlobal New testing proves Tristel chlorine dioxide destroys SARS-CoV-2, the virus responsible for the COVID-19 pandemic, in 30 seconds. Find out more: https://tristel.com/uk/news
piedro
23/10/2020
15:34
Nicely put, mighunter. Let's keep the politesse 😊 apad
apad
23/10/2020
13:51
I also take the view that ongoing reevaluation of the pros and cons of a share is necessary, particularly when seismic events - such as those we are experiencing at the moment - occur. New products will inevitably appear over time, but it will be a relatively long haul before they are approved by the main regulatory authorities. Look at what TSTL are going through in the US with the FDA for products that have been widely approved in numerous other jurisdictions. After that, health authorities and other consumers have to be persuaded to switch from products that have been heavily scrutinised and approved. Surely it would be easier for one of the bigger players to simply acquire TSTL. That has to be the most likely endgame. The US is not the be-all and end-all, but it is one of the most obvious jurisdictions from which a buyer may emerge. I wonder if that is one of the main reasons that TSTL has decided to really ramp up its approval programmes with both the FDA and the EPA. It is not that long ago - less than twelve months,I believe - that TSTL scaled back the number of products in its FDA programme. At that point, the focus was all about Duo for ultrasound devices. Based on the final results and the supporting presentation earlier this week, it now appears that the US programme is receiving a big push, with a substantially increased supporting budget. Interesting times.
james188
23/10/2020
12:02
LOL, mighunter, correct I started this thread in 2008 and started contributing a couple of years earlier. You will note that I subscribed "AIMHO" which indicates that I am expressing my opinion. Why after all this time? Basically, TSTL have started plugging their "moat" - IMO
piedro
23/10/2020
12:00
Ignore that please Piedro. Your posts are insightful and it is always good to challenge yourself to find potential negatives with your holdings.
hydrus
23/10/2020
11:29
Piedro, a 2 second search of your post history shows you posting on TSTL as early as 2008 - if not before. Why you ask the basic questions you initially have, when the answers have been freely available to seek in those intervening 12 years, I do not know. So what credible information do you actually possess, leading you to suggest that other companies could already be in the process of adopting similar technology.... and further, what proof do you have of it being maybe in a year. And why now rather than any other point in your 12 year history posting on TSTL, as your argument certainly hasn't come true in that timeframe. If you're going to suggest such speculative hunches, it'll need a better explanation you stating that the dinosaurs are now extinct.
mighunter
23/10/2020
11:08
... they'll be accusing me of hogging too much space, but to return to the previous topic Do Dinosaurs still walk the earth? Times have changed and those old moat arguments need rethinking There are Companies that have the resources to compete, perhaps in a year or so, but more likely they are already in the process. I still remember the affair with Chlorox. AIMHO, BWDIK .. ... DYOR and GLA :-)
piedro
23/10/2020
10:54
To change the subject, FWIW ...
piedro
20/10/2020
22:13
So as at 2018 they're the only company in 25 years to use this. In 2017, they had 229 patents covering 35 countries... the proprietary information covers both formulation and delivery. .....I'd say there's a moat.
mighunter
20/10/2020
13:22
Tis a good question, Piedro. I'm happy with first mover advantage. Difficult to come in and compete, from scratch. apad
apad
20/10/2020
13:18
Rereading the Final Results I stopped to consider... Our Strategic Assets "We consider the assets that enable the Group to achieve its strategic goals to be: - Our chlorine dioxide chemistry, about which there are three critically important elements: 1. The formulation is proprietary; 2. We remain the only company using chlorine dioxide for the decontamination of medical instruments in the world, which gives us a genuine point of difference from all other infection prevention companies; 3. The length of time that we have enjoyed this position has allowed us to collate a significant body of knowledge, including published scientific data, the testimony of almost two decades of safe use, a significant global footprint of regulatory approvals and a library of proven compatibility with hundreds of medical instruments, all of which would take a newcomer significant time and cost to match." ... and ask How proprietary is the formulation? {element 1} Cannot someone else invent a different formulation? When ClO2 becomes the "vogue" there may well be many trying to enter the market {element 2} and fortunately for them the groundwork has already been done {element 3}. Is their moat really that strong? P.
piedro
20/10/2020
08:40
Complete cobblers! International growth is already booming for TSTL. The USA is a huge bonus sure but the length of time it is taking means a huge barrier to entry for others. Biden will I assume be more health care friendly than Top Trump. India is a huge market and will be finalised soon. Yield is only 1.2% but I can plough that back in and grow my holdings. They will have to do something with the cash pile which I think from memory grew 50% to £6 million so there will be a nice return in the way of a special divi at some point. Investor's Chumping more like!
mach100
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
ADVFN Advertorial
Your Recent History
LSE
TSTL
Tristel
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201129 16:54:57